ArticleObesity reviews : an official journal of the International Association for the Study of Obesity2024
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss.
Article in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population.Endocrinology, diabetes & metabolism · 2026Article
- Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study.BMC public health · 2026Article
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open · 2026Review
- Game, Set, and Match: A Scoping Review of Matching Characteristics for Control and Intervention Groups in Adaptive Behavioral Interventions for Physical Activity or Healthy Eating Designs for Populations with Overweight and Obesity.Behavioral medicine (Washington, D.C.) · 2026Review
- Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations.Aesthetic surgery journal. Open forum · 2026Article
- Oral Treatment of Obesity by GLP-1 and Its Analogs.Pharmaceutics · 2025Review
- Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?Current atherosclerosis reports · 2025Review
- GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status?Current developments in nutrition · 2025Article
- Updates on Anti-Obesity Medications in Children and Adolescents.Children (Basel, Switzerland) · 2025Review
- GLP-1 Receptor Agonists for Treatment of Pediatric Obesity: Behavioral Health Considerations.Childhood obesity (Print) · 2025Review
- Are recent decreases in adult obesity trends in the United States encouraging or alarming?Preventive medicine · 2025Article
- The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort.Biomedicines · 2025Article
- Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps.Clinical endocrinology · 2025Review
- Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss.PLOS global public health · 2025Article
- Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes. These medications, leveraging the effects of the insulin-regulating hormone GLP-1 via actions on peripheral and central nervous system targets, have raised hopes with their bariatric surgery-rivaling results. However, questions remain about their long-term safety and efficacy. Drawing from our expertise in obesity medicine and psychiatry, we reflect upon our experiences with the clinical use of these medications and delve into the nuanced challenges and risks they pose, particularly for those prone to disordered eating or those diagnosed with rare genetic diseases of obesity. We contend that effectively managing weight loss within this "danger zone" necessitates (1) proactive screening and continuous monitoring for disordered eating, (2) vigilant monitoring for appetite-related maladaptive responses, including food aversion and dehydration, and (3) ongoing assessment for broader health impacts. A multifaceted, interdisciplinary approach that melds medical, psychological, dietary, and behavioral strategies is crucial to delivering tailored and thorough care to each patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.